Lucid Diagnostics Revenue and Competitors
Estimated Revenue & Valuation
- Lucid Diagnostics's estimated annual revenue is currently $27.9M per year.
- Lucid Diagnostics's estimated revenue per employee is $251,000
Employee Data
- Lucid Diagnostics has 111 Employees.
- Lucid Diagnostics grew their employee count by -2% last year.
Lucid Diagnostics's People
Name | Title | Email/Phone |
---|---|---|
1 | Director Marketing, Communications | Reveal Email/Phone |
Lucid Diagnostics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $160M | 800 | 4% | $323.5M | N/A |
#2 | $9.3M | 37 | 12% | N/A | N/A |
#3 | $36.4M | 145 | 2% | N/A | N/A |
#4 | $7M | 28 | 0% | N/A | N/A |
#5 | $1M | 4 | -88% | N/A | N/A |
#6 | $7.5M | 21 | -9% | $6.5M | N/A |
#7 | $6M | 24 | 4% | N/A | N/A |
#8 | $13.1M | 52 | 4% | N/A | N/A |
#9 | $17.1M | 68 | -17% | N/A | N/A |
#10 | $27.9M | 111 | 4% | N/A | N/A |
What Is Lucid Diagnostics?
Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard® Esophageal DNA Test, performed on samples collected in a brief noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients. EsoGuard is commercialized in the U.S. as a Laboratory Developed Test (LDT). EsoCheck is commercialized in the U.S. as a 510(k)-cleared esophageal cell collection device. EsoGuard, used with EsoCheck, was granted FDA Breakthrough Device designation and is the subject of two large, actively enrolling, international multicenter clinical trials to support FDA PMA approval. Lucid is building a network of Lucid Test Centers where at-risk GERD patients can undergo the EsoCheck procedure for EsoGuard testing.
keywords:N/AN/A
Total Funding
111
Number of Employees
$27.9M
Revenue (est)
-2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Lucid Diagnostics News
Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with...
Lucid Diagnostics Inc is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. Lucid is focused on...
Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $16.1M | 111 | 3% | N/A |
#2 | $30M | 111 | 52% | N/A |
#3 | $25.3M | 111 | 4% | N/A |
#4 | $25.2M | 111 | 2% | N/A |
#5 | $24.4M | 111 | 26% | N/A |